World’s first intra-nasal vaccine for COVID developed by India has got approval from the CDSCO for restricted use in emergency situations in the age group of 18 and above

Source: The post is based on the articleWorld’s first intra-nasal vaccine for COVID developed by India has got approval from the Central Drugs Standard Control Organisation (CDSCO) for restricted use in emergency situations in the age group of 18 and abovepublished in PIB on 2nd December 2022.

What is the News?

World’s first intra-nasal vaccine for COVID named “iNCOVACC” has got approval from the Central Drugs Standard Control Organisation (CDSCO) for restricted use in emergency situations in the age group of 18 and above.

What is iNCOVAC Vaccine?
iNCOVAC Vaccine
Source: TOI

iNCOVAC (BBV154) is the World’s first intra-nasal vaccine.

Developed by: Bharat Biotech International Limited (BBIL)

The product development and Clinical trials of the vaccine were funded by the Department of biotechnology and BIRAC under the Mission COVID Suraksha Program.

Click here to read more about the vaccine

What are the other decisions taken by the Government?

Formation of Biotechnology Research and Innovation Council(BRIC) 

BRIC will be an apex autonomous body of the Department of Biotechnology(DBT). It has been formed by subsuming 14 Autonomous Institutions of DBT.

Aim: To achieve centralized and unified governance to maximize the impact of biotech research.

Print Friendly and PDF